Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting Covid-19 by 81.6 percent in the two to eight months period following the drug's administration in a late-stage trial.

The results showed that antibody therapy, Regen-Cov, has the potential to provide long-lasting immunity from Covid-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the US National Institutes of Health-sponsored Covid Prevention Network.

Such immunity is particularly important for immunocompromised people...